Rite Aid has struggled with declining sales, growing debt, and legal claims connecting it to the opioid crisis. Intense competition from rivals, emphasizing healthcare services, compounds its challenges.
In the quarter ending June 3, revenue dropped to $5.6 billion from $6.01 billion a year ago. Net losses increased to $306.7 million, or $5.56 per share, compared to $110.2 million, or $2.03 per share, in the corresponding period last year.
Due to a challenging quarter, Rite Aid revised its fiscal 2024 forecast, cautioning investors about an anticipated full-year loss of $650 million to $680 million, concluding in late February.
Drugstores like Rite Aid grapple with an existential challenge as consumers increasingly opt for Amazon, Target, Walmart, and similar retailers, offering lower prices and doorstep convenience for everyday essentials.